Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

Table 1 Direct acting antivirals commenced on patients with decompensated cirrhosis or recipients after liver transplantation

Approved protease inhibitors
Boceprevir	NS3-4A serine protease inhibitors
Telaprevir	Second-wave NS3/4A protease inhibitor
Simeprevir
Approved NS5A inhibitors
Daclatasvir	NS5A inhibitor
Approved NS5B RNA-dependent RNA polymerase nucleotide inhibitor
Sofosbuvir	NS5B RNA-dependent RNA polymerase nucleotide inhibitor
Newer DAAs evaluated in combination regimens without Peg-IFN
Ledipasvir (formerly GS-5885)	NS5A inhibitor
ABT-450	NS3/4A protease inhibitor
Ombitasvir (formerly ABT-267)	NS5A inhibitor
Dasabuvir (formerly ABT-333)	Non-nucleoside NS5B polymerase inhibitor

Peg-IFN: Pegylated interferon.